WO2004066967A3 - Method and kit for reducing the symptoms of peripheral vascular disease - Google Patents
Method and kit for reducing the symptoms of peripheral vascular disease Download PDFInfo
- Publication number
- WO2004066967A3 WO2004066967A3 PCT/US2004/000941 US2004000941W WO2004066967A3 WO 2004066967 A3 WO2004066967 A3 WO 2004066967A3 US 2004000941 W US2004000941 W US 2004000941W WO 2004066967 A3 WO2004066967 A3 WO 2004066967A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peripheral vascular
- symptoms
- vascular disease
- reducing
- kit
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04702515A EP1594510A4 (en) | 2003-01-21 | 2004-01-15 | Method and kit for reducing the symptoms of peripheral vascular disease |
JP2006502824A JP2006515890A (en) | 2003-01-21 | 2004-01-15 | Methods and kits for symptoms of peripheral vascular disease |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/348,570 | 2003-01-21 | ||
US10/348,570 US7572780B2 (en) | 2003-01-21 | 2003-01-21 | Method and kit for reducing the symptoms of peripheral vascular disease |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2004066967A2 WO2004066967A2 (en) | 2004-08-12 |
WO2004066967A3 true WO2004066967A3 (en) | 2005-03-03 |
WO2004066967B1 WO2004066967B1 (en) | 2005-04-14 |
Family
ID=32712580
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/000941 WO2004066967A2 (en) | 2003-01-21 | 2004-01-15 | Method and kit for reducing the symptoms of peripheral vascular disease |
Country Status (4)
Country | Link |
---|---|
US (3) | US7572780B2 (en) |
EP (1) | EP1594510A4 (en) |
JP (1) | JP2006515890A (en) |
WO (1) | WO2004066967A2 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2782584B1 (en) | 2011-11-23 | 2021-06-09 | TherapeuticsMD, Inc. | Natural combination hormone replacement formulations and therapies |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
NZ704247A (en) * | 2012-07-27 | 2018-04-27 | Glia Llc | Compositions and treatment for eye diseases and disorders |
US9381231B2 (en) | 2012-10-09 | 2016-07-05 | University Of Florida Research Foundation, Inc. | Use of relaxin to restore maternal physiology in pregnancies conceived by assisted reproductive technologies |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
JP2017516768A (en) | 2014-05-22 | 2017-06-22 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | Natural combination hormone replacement therapy and therapy |
US10098894B2 (en) | 2014-07-29 | 2018-10-16 | Therapeuticsmd, Inc. | Transdermal cream |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
WO2017173071A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0399432A2 (en) * | 1989-05-25 | 1990-11-28 | Takeda Chemical Industries, Ltd. | Transdermal therapeutic composition |
US5612051A (en) * | 1995-11-17 | 1997-03-18 | Yue; Samuel K. | Method of treating involuntary muscle dysfunction with relaxin hormone |
US20020156090A1 (en) * | 2000-10-17 | 2002-10-24 | Day Wesley W. | Methods and kits for improving vascular health |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2408345A1 (en) * | 1976-11-30 | 1979-06-08 | Besins Jean Louis | NEW COMPOSITION WITH ANTI-CONCEPTIONAL ACTION |
DE3514724A1 (en) | 1985-04-24 | 1986-10-30 | Albin F. Dr. 4200 Oberhausen Jereb | Ointment for the prevention and treatment of disorders of the eyes and skin |
US4788062A (en) | 1987-02-26 | 1988-11-29 | Alza Corporation | Transdermal administration of progesterone, estradiol esters, and mixtures thereof |
US4900734A (en) * | 1987-08-27 | 1990-02-13 | Maxson Wayne S | Novel pharmaceutical composition containing estradiol and progesterone for oral administration |
US5422119A (en) * | 1987-09-24 | 1995-06-06 | Jencap Research Ltd. | Transdermal hormone replacement therapy |
US4800734A (en) * | 1987-11-02 | 1989-01-31 | White Consolidated Industries, Inc. | Room air conditioner |
US5543150A (en) | 1993-09-15 | 1996-08-06 | Columbia Laboratories, Inc. | Method of progesterone delivery and affect thereof |
US5859001A (en) * | 1996-01-11 | 1999-01-12 | University Of Florida Research Foundation, Inc. | Neuroprotective effects of polycyclic phenolic compounds |
US5693629A (en) | 1994-04-04 | 1997-12-02 | Meiji Milk Products Co., Ltd. | Progesterone compound and use thereof |
US5696123A (en) * | 1994-09-17 | 1997-12-09 | Boehringer Ingelheim Kg | Neurokinin antagonists |
US6613757B1 (en) | 1994-09-22 | 2003-09-02 | Board Of Regents, The University Of Texas System | Combination of prostacyclin with an estrogen or progestin for the prevention and treatment of atherosclerotic vascular disease including preeclampsia and for the treatment of hypertension, and for hormone replacement therapy |
JPH08180574A (en) * | 1994-12-28 | 1996-07-12 | Teac Corp | Disc unit |
US5744463A (en) | 1996-06-03 | 1998-04-28 | Bair; Glenn O. | Treatment of side effects of progestins and progesterone analogues used for birth control |
IT1283102B1 (en) * | 1996-06-06 | 1998-04-07 | Permatec Nv | THERAPEUTIC COMPOSITION FOR THE TRANSDERMAL ADMINISTRATION OF AN ESTROGENIC OR PROGESTINIC ACTIVE SUBSTANCE OR OF THEIR MIXTURES |
US6228852B1 (en) * | 1996-07-12 | 2001-05-08 | Carolyn V. Shaak | Transdermal application of naturally occurring steroid hormones |
US5985861A (en) * | 1996-11-04 | 1999-11-16 | Columbia Laboratories, Inc. | Progesterone for treating or reducing ischemia |
US6056972A (en) * | 1997-02-26 | 2000-05-02 | Dimera, Llc | Method for reducing coronary artery reactivity |
US6440954B1 (en) * | 1997-04-18 | 2002-08-27 | President And Fellows Of Harvard College | Inhibition of vascular smooth muscle cell proliferation |
US5998638A (en) * | 1997-05-02 | 1999-12-07 | American Home Products Corporation | Ester salt of 5α-pregn-16-en-3β-ol-20-one 3-sulfate |
KR20010012156A (en) | 1997-05-02 | 2001-02-15 | 이곤 이 버그 | Pregnane-3,20-diol mono- and di-sulphates |
KR20010012157A (en) | 1997-05-02 | 2001-02-15 | 이곤 이 버그 | Pregnan-3-ol-20-ones |
US5968918A (en) * | 1997-10-17 | 1999-10-19 | Kanda; Iwao | Method for the prevention of coronary artery spasm |
US5988918A (en) * | 1998-04-24 | 1999-11-23 | Johnson; Gary D. | Flat folding writing instrument |
AU2609401A (en) | 1999-12-29 | 2001-07-09 | Nicholas Kipshidze | Apparatus and method for delivering compounds to a living organism |
EP1539183A4 (en) | 2002-08-28 | 2007-04-25 | Hollis Eden Pharmaceuticals | Therapeutic treatment methods |
AU2003272378A1 (en) | 2002-09-12 | 2004-04-30 | X-Cell Medical, Inc. | Apparatus and method for delivering compounds to a living organism |
-
2003
- 2003-01-21 US US10/348,570 patent/US7572780B2/en not_active Expired - Fee Related
-
2004
- 2004-01-15 WO PCT/US2004/000941 patent/WO2004066967A2/en active Application Filing
- 2004-01-15 JP JP2006502824A patent/JP2006515890A/en active Pending
- 2004-01-15 EP EP04702515A patent/EP1594510A4/en not_active Ceased
-
2009
- 2009-07-02 US US12/459,579 patent/US8182833B2/en not_active Expired - Fee Related
-
2012
- 2012-05-21 US US13/476,443 patent/US8420111B2/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0399432A2 (en) * | 1989-05-25 | 1990-11-28 | Takeda Chemical Industries, Ltd. | Transdermal therapeutic composition |
US5612051A (en) * | 1995-11-17 | 1997-03-18 | Yue; Samuel K. | Method of treating involuntary muscle dysfunction with relaxin hormone |
US20020156090A1 (en) * | 2000-10-17 | 2002-10-24 | Day Wesley W. | Methods and kits for improving vascular health |
Non-Patent Citations (3)
Title |
---|
DATABASE CAPLUS [online] WALKER T.C.: "Use of testosterone propionate and estrogenic substance in treatment of essential hypertension, angina pectoris and peripheral vascular disease", XP002984534, Database accession no. 1943:5455 * |
JOURNAL OF CLINICAL ENDOCRINOLOGY, vol. 2, 1942, pages 560 - 568 * |
MYERS ET AL.: "Estrogen increase male rat aortic endothelial cell (RAEC) PGI2 release", PROSTAGLANDINS, LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, vol. 54, no. 6, 1996, pages 403 - 409, XP002984535 * |
Also Published As
Publication number | Publication date |
---|---|
WO2004066967A2 (en) | 2004-08-12 |
US20040142913A1 (en) | 2004-07-22 |
WO2004066967B1 (en) | 2005-04-14 |
EP1594510A2 (en) | 2005-11-16 |
US20090275544A1 (en) | 2009-11-05 |
US7572780B2 (en) | 2009-08-11 |
US8420111B2 (en) | 2013-04-16 |
EP1594510A4 (en) | 2008-07-23 |
US8182833B2 (en) | 2012-05-22 |
US20120232046A1 (en) | 2012-09-13 |
JP2006515890A (en) | 2006-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004066967A3 (en) | Method and kit for reducing the symptoms of peripheral vascular disease | |
WO2004103959A3 (en) | Heterocyclic compounds and uses thereof | |
WO2007034188A3 (en) | Chemo-immunotherapy method | |
WO2001085154A3 (en) | Method of treating immune pathologies with low dose estrogen | |
WO2005097119A3 (en) | Pten inhibitors | |
ZA200608024B (en) | Use of flibanserin in the treatment of premenstrual and other female sexual disorders | |
WO2006068760A3 (en) | Anti-inflammatory pyrazolopyrimidines | |
HK1075010A1 (en) | Gaba enhancers in the treatment of diseases relating to reduced neurosteroid activity | |
WO2005037323A3 (en) | Use of gro to treat or prevent inflammation | |
EP1767197A3 (en) | Treatment of Alzheimer's disease with inhibitors of cell cycle re-entry and progression | |
WO2006004449A3 (en) | A combination composition | |
WO2004090539A3 (en) | Methods of determining efficacy of treatments of inflammatory diseases of the bowel | |
EP1750734A4 (en) | Method of preparation and use of fibrinolytic enzymes in the treatment of disease | |
WO2006042021A3 (en) | Methods of hormonal treatment utilizing ascending-dose extended cycle regimens | |
WO2004098517A8 (en) | Methods of hormonal treatment utilizing extended cycle contraceptive regimens | |
WO2006016262A8 (en) | Combination of a selective noradrenaline reuptake inhibitor and a pdev inhibitor | |
WO2004047792A3 (en) | Liposomal glucocorticoids | |
WO2005046657A3 (en) | Use of an inhibitor of csf-1 activity for the treatment of inflammatory bowel disease | |
WO2004103407A3 (en) | Composition comprising a pde4 inhibitor and a pde5 inhibitor | |
CA2387486A1 (en) | Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders | |
WO2004028548A3 (en) | Inhibitors of the nitrix oxide synthase iii (nos iii) as neuroprotective agents | |
WO2006138571A3 (en) | Composition and methods for treating complications associated with ingestion of a medicinal, chemical or biological substance | |
AU2003291536A1 (en) | Method for the diagnosis and treatment of vascular disease | |
WO2006102899A3 (en) | Oxaprozin or closely related compound for the treatment and prevention of | |
CA2436511A1 (en) | Use of flumazenil to produce a medicament for the treatment of cocaine dependency |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
B | Later publication of amended claims |
Effective date: 20050207 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006502824 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004702515 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004702515 Country of ref document: EP |